Resistance to Anti-Cancer Therapeutics Targeting Receptor Tyrosine Kinases and Downstream Pathways

This volume comprehensively covers the multiplicity and diversity of mechanisms underlying patient resistance to currently approved anti-cancer drugs, including tyrosine kinase inhibitors and monoclonal antibodies, blockers of growth factor receptors and their downstream pathways, which play essenti...

Full description

Saved in:
Bibliographic Details
Format: Electronic eBook
Language:English
Published: Cham : Springer International Publishing, 2018.
Edition:1st ed. 2018.
Series:Resistance to Targeted Anti-Cancer Therapeutics, 15
Subjects:
Cancer research.
ISBN:9783319679327
ISSN:2196-5501 ;
Online Access: Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Table of Contents:
  • Resistance of colorectal tumors to anti-EGFR antibodies
  • Resistance of lung cancer to kinase inhibitors specific to EGFR or ALK
  • Mechanisms of action and resistance of trastuzumab in breast cancer
  • Mechanisms of resistance to molecular therapies targeting the HGF/MET axis
  • RAF, MEK and ERK inhibitors as anti-cancer drugs: intrinsic and acquired resistance as a major therapeutic challenge
  • Mechanisms of resistance to PI3K and AKT inhibitors
  • Sensitivity and resistance to BH3 mimetics in cancer therapy
  • Resistance mechanisms to cyclin-dependent kinase inhibitors
  • Resistance to inhibitors of angiogenesis.

Similar Items